Suppliers / Hill Dermaceuticals

Hill Dermaceuticals

United States 60 employees Updated 9 July 2026

Hill Dermaceuticals is a finished-dose manufacturer based in United States. It appears in 19 regulatory filings across 6 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, ARCSA (EC) and MINSA (CR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 October 2025 as VAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
19
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 October 2025 VAI US FDA
  • 11 August 2021 VAI US FDA
  • 18 May 2018 VAI US FDA
  • 6 October 2014 VAI US FDA
  • 10 August 2012 OAI US FDA
  • 30 March 2012 OAI US FDA
  • 10 September 2010 OAI US FDA
  • 19 February 2010 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Sanford, United Arab Emirates Not on file
SANFORD, United States 1036365

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 14 None
ARCSA (EC) 1 None
MINSA (CR) 1 None
US FDA 1 1
EDE (AE) 1 None
NPRA (MY) 1 None

Comparing suppliers?

Choose your molecules and target markets. Hill Dermaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 October 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates